Business
Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)
Supported by promising data generated during the option period, Coya has entered into an exclusive license for a next-generation EET platform to enable
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"\n\nSupported by promising data generated during the option period, Coya has entered into an exclusive license for a next-generation EET platform to enable engineering of exosomes with potential to target epitope driven neurodegenerative, autoimmune and oncologic diseases;\n\n\n\nExosomes are a nanometer-sized type of extracellular vesicle that can be shed from every cell in the body- Researchers have attempted to harness the exosome as a drug delivery vehicle, but techniques previously developed required the use of complex molecular biology tools or degraded the exosome’s functionality;\n\n\n\nThis patented technology requires no genetic modifications, overcomes known limitations of exosome manipulation, and also enables tethering proteins of interest to the exosome surface and loading cargo of interest within the exosome interior;\n\n\n\nData was recently presented at the 5th Exosome Based Therapeutic Development Summit successfully engineering a surface protein, cytotoxic T lymphocyte associated protein 4 (CTLA-4) on to Regulatory T cell (Treg) exosomes to increase selective targeting to immune cells;\n\n\n\nEET expands Coya’s optionality for potential non-dilutive business development and strategic partnerships with companies seeking innovative drug and RNA delivery platforms that may be selectively targeted to proteins or epitopes that drive disease.\n\n\n\n HOUSTON--(BUSINESS WIRE)--\nCoya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Tregs, today announced licensing of the exclusive, worldwide rights of a proprietary Exosome Engineering Technology from CMU with potential applications across multiple indications, including neurodegeneration, autoimmune, and oncology.\n\n\nThis technology is versatile, permitting the modification of exosomes from different biological sources while overcoming several of the scale-up and manufacturing challenges encountered with exosomes, including not requiring genetic manipulation. In addition, the ability to customize the surface of the exosome with a protein of interest while loading the interior of the exosome with cargo opens possibilities across multiple therapeutic areas beyond neurodegenerative diseases.\n\n\nData was recently presented at the 5th Exosome ...